Cardiovascular Drugs Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2015 to 2020 and Forecast 2021 to 2027

$ PRICE - $ 3,000.00$ 8,900.00

Global Cardiovascular Drugs Market By Disease Type (Hypertension, Congestive Heart disease, Angina pectoris, Myocardial Ischemia, Peripheral Artery Diseases, Atherosclerosis, Cardiomyopathy, Others), By Drug Class (Anti-hypertensive Drugs, Lipid lowering drugs, Beta-adrenergic Blocking Agents, Vasodilators, Anti-platelet Agents, Others), By Route of Administration (Oral, Buccal/sublingual, Intravenous, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

The global cardiovascular drugs market size valued $87.79 billion in 2020 and expected to reach $119.87 billion in 2027, at a CAGR of 4.8% during forecast period 2021-2027. Cardiovascular drugs are the medications used in the treatment of various cardiovascular diseases. Cardiovascular diseases (CVD) include coronary artery diseases (CAD), myocardial infarction, angina pectoris, hypertension, cardiomyopathy, congenital heart disease, cardiac arrhythmia, peripheral artery diseases, atherosclerosis, and venous thrombosis among others. Majority of the cardiovascular diseases are preventable with cardiovascular drugs, however, in frequent conditions death may occur due to cardiovascular diseases. Global Market has tremendous growth rate over the forecast years owing to increase in the prevalence of various cardiovascular diseases and rise in R&D activities for the innovation of newer drugs. According to World Health Organization 2015, approximately 17.7 Mn deaths occured due to cardiovascular diseases around the world. Moreover, government support to control the diseases, rise in funding from public and private sectors for the R&D activities, and patent expiration of blockbuster are bolster the cardiovascular drugs market. Furthermore, acquisitions and mergers, product approvals, and promising pipeline drugs might upsurge the revenue of cardiovascular drugs market. For instance, in November 2015, AstraZeneca acquired ZS Pharma to strengthen its cardiovascular drugs portfolio by developing novel treatment for hyperkalemia, typically associated with chronic heart failure (CHF). In addition, in June 2016, Espero Pharmaceuticals received FDA approval for Gonitro (Nitroglycerin) sublingual powder used for acute relief of an angina pectoris attack due to coronary artery disease.

Cardiovascular Drugs Market

MARKET SUMMARY
-
4.8% CAGR
  • Study Period– 2021 – 2027
  • Base Year– 2020
  • CAGR– 4.8%
  • Largest Market– North America
  • Fastest Growing Market–  Europe

Cardiovascular Drugs Market

  • The report on global cardiovascular drugs market gives historical, current and future market sizes (US$ Bn) on the basis of indication, drug class, route of administration, distribution channel and region.
  • cardiovascular drugs market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
Key Players
  • AstraZeneca plc
  • Bristol Myers Squibb
  • Boehringer Ingelheim GmbH
  • Bayer AG
  • Merck & Co., Inc.
  • Espero Pharmaceuticals, Inc.
Cardiovascular Drugs Market

Drivers And Restraints

Increase in the prevalence of cardiovascular diseases, for instance, according to World health organization 2015, approximately 17.7 Mn people died from cardiovascular diseases around the globe, rise in R&D activities for the innovation of newer cardiovascular drugs, government support to increase the awareness about the cardiovascular diseases and treatment are anticipated to fuel the cardiovascular drugs market. Moreover, change in lifestyle, promising product pipeline, rise in prevalence of obesity, and wider access to cardiovascular drugs in the market are anticipated to propel the market. However, stringent regulatory guidelines for the product approval, high cost of treatment, and adverse effects associated with the medications are hampering the growth of cardiovascular drugs market.


North-America got significant share

Cardiovascular Drugs Market

Geographically, Global Market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America accounted for significant share owing to increase in the prevalence of cardiovascular diseases (according to centers for Disease Control and Prevention, approximately 610,000 deaths occur due to various heart diseases in U.S. every year) and rise in R&D activities in North America region. Europe exhibiting lucrative growth due to increase in incidences of cardiovascular diseases majorly in Germany, Russia, UK, Ukraine, and Italy. Asia Pacific is growing at notable rate due to increase in geriatric population in India, China, and Japan, rise in medical tourism in Asia Pacific countries, and government support for the prevention of cardiovascular diseases in various countries. Latin America has significant growth which is attributed to increase in prevalence of cardiovascular diseases in Chile, Argentina, and Brazil. Middle East and Africa is growing due to expansion of business by market players, rise in prevalence of cardiovascular diseases, and government support to protect the public health.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Notable Market Developments

  • In February 2017, Pfizer, Inc. and Washington University collaborated to develop newer drugs in certain therapeutic areas include cardiovascular diseases

Key

Key Features of the Report

Cardiovascular Drugs Market Segmentation


Location

GEOGRAPHY


Report

Table Of Content

  1. Table of Content
  2. Executive Summary
  3. Global Cardiovascular Drugs Market Introduction
    • Global Cardiovascular Drugs Market – Taxonomy
    • Global Cardiovascular Drugs Market –Definitions
      • Indication
      • Drug Class
      • Route of Administration
      • Distribution Channel
  1. Global Cardiovascular Drugs Market Dynamics
    • Drivers
    • Restraints
    • Opportunities/Unmet Needs of the Market
    • Trends
    • Global Cardiovascular Drugs Market Dynamic Factors – Impact Analysis
    • Global Cardiovascular Drugs Market – Competition Landscape
    • Epidemiology
  2. Global Cardiovascular Drugs Market Analysis,2013 – 2017 and Forecast, 2018 – 2024
    • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Year-over-Year (Y-o-Y) Growth Analysis (%)
    • Market OpportunityAnalysis
  3. Global Cardiovascular Drugs Market, By Indication, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Hypertension
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Congestive Heart disease
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Angina pectoris
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Myocardial Ischemia
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Peripheral Artery Diseases
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Atherosclerosis
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Cardiomyopathy
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Others
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Cardiovascular Drugs Market Forecast, By Drug Class,2013 – 2017 and Forecast, 2018 – 2024
    • Calcium Channel Blockers
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Angiotensin Converting Enzyme (ACE) inhibitors
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Angiotensin-II Receptor antagonists
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Diuretics
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Lipid-lowering drugs
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Beta-adrenergic Blocking Agents
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Vasodilators
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Anti-platelet Agents
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Others
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Cardiovascular Drugs Market Forecast, By Route of Administration, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Oral
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Buccal/sublingual
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Intravenous
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Others
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Cardiovascular Drugs Market Forecast, By Distribution Channel, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Hospital Pharmacies
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Retail Pharmacies
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Online Pharmacies
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Cardiovascular Drugs Market Forecast, By Region, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • North America
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Europe
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Asia-Pacific
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Latin America
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Middle East and Africa
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Global Cardiovascular Drugs Market – Opportunity Analysis Index, By Indication, By Drug Class, By Route of Administration, By Distribution Channel, and Region, 2018 – 2024
  2. North America Cardiovascular Drugs MarketAnalysis,2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Indication Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Hypertension
      • Congestive Heart disease
      • Angina pectoris
      • Myocardial Ischemia
      • Peripheral Artery Diseases
      • Atherosclerosis
      • Cardiomyopathy
      • Others
    • Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Calcium Channel Blockers
      • Angiotensin Converting Enzyme (ACE) inhibitors
      • Angiotensin-II Receptor antagonists
      • Diuretics
      • Lipid-lowering drugs
      • Beta-adrenergic Blocking Agents
      • Vasodilators
      • Anti-platelet Agents
      • Others
    • Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Buccal/sublingual
      • Intravenous
      • Others
    • Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis 2016 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • US
      • Canada
    • North America Cardiovascular Drugs Market – Opportunity Analysis Index, By Indication, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2018 – 2024
    • North America Cardiovascular Drugs Market Dynamics – Trends
  3. Europe Cardiovascular Drugs Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Indication Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Hypertension
      • Congestive Heart disease
      • Angina pectoris
      • Myocardial Ischemia
      • Peripheral Artery Diseases
      • Atherosclerosis
      • Cardiomyopathy
      • Others
    • Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Calcium Channel Blockers
      • Angiotensin Converting Enzyme (ACE) inhibitors
      • Angiotensin-II Receptor antagonists
      • Diuretics
      • Lipid-lowering drugs
      • Beta-adrenergic Blocking Agents
      • Vasodilators
      • Anti-platelet Agents
      • Others
    • Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Buccal/sublingual
      • Intravenous
      • Others
    • Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Germany
      • UK
      • France
      • Spain
      • Italy
      • Russia
      • Poland
      • Rest of Europe
    • Europe Cardiovascular Drugs Market – Opportunity Analysis Index, By Indication, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2018 – 2024
    • Europe Cardiovascular Drugs Market Dynamics – Trends
  4. Asia-Pacific Cardiovascular Drugs Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Indication Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Hypertension
      • Congestive Heart disease
      • Angina pectoris
      • Myocardial Ischemia
      • Peripheral Artery Diseases
      • Atherosclerosis
      • Cardiomyopathy
      • Others
    • Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Calcium Channel Blockers
      • Angiotensin Converting Enzyme (ACE) inhibitors
      • Angiotensin-II Receptor antagonists
      • Diuretics
      • Lipid-lowering drugs
      • Beta-adrenergic Blocking Agents
      • Vasodilators
      • Anti-platelet Agents
      • Others
    • Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Buccal/sublingual
      • Intravenous
      • Others
    • Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Japan
      • China
      • India
      • ASEAN
      • Australia & New Zealand
      • Rest of Asia-Pacific
    • Asia-Pacific Cardiovascular Drugs Market – Opportunity Analysis Index, By Indication, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2018 – 2024
    • Asia-Pacific Cardiovascular Drugs Market Dynamics – Trends
  5. Latin America Cardiovascular Drugs Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Indication Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Hypertension
      • Congestive Heart disease
      • Angina pectoris
      • Myocardial Ischemia
      • Peripheral Artery Diseases
      • Atherosclerosis
      • Cardiomyopathy
      • Others
    • Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Calcium Channel Blockers
      • Angiotensin Converting Enzyme (ACE) inhibitors
      • Angiotensin-II Receptor antagonists
      • Diuretics
      • Lipid-lowering drugs
      • Beta-adrenergic Blocking Agents
      • Vasodilators
      • Anti-platelet Agents
      • Others
    • Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Buccal/sublingual
      • Intravenous
      • Others
    • Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Brazil
      • Mexico
      • Argentina
      • Venezuela
      • Rest of Latin America
    • Latin America Cardiovascular Drugs Market – Opportunity Analysis Index, By Indication, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2018 – 2024
    • Latin America Cardiovascular Drugs Market Dynamics – Trends
  6. Middle East and Africa Cardiovascular Drugs Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Indication Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Hypertension
      • Congestive Heart disease
      • Angina pectoris
      • Myocardial Ischemia
      • Peripheral Artery Diseases
      • Atherosclerosis
      • Cardiomyopathy
      • Others
    • Drug Class Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Calcium Channel Blockers
      • Angiotensin Converting Enzyme (ACE) inhibitors
      • Angiotensin-II Receptor antagonists
      • Diuretics
      • Lipid-lowering drugs
      • Beta-adrenergic Blocking Agents
      • Vasodilators
      • Anti-platelet Agents
      • Others
    • Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Buccal/sublingual
      • Intravenous
      • Others
    • Distribution Channel Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Gulf Cooperation Council (GCC) Countries
      • Israel
      • South Africa
      • Rest of MEA
    • MEA Cardiovascular Drugs Market – Opportunity Analysis Index, By Indication, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2018 – 2024
    • MEA Cardiovascular Drugs Market Dynamics – Trends
  7. Competition Landscape
    • Strategic Dashboard of Top Market Players
    • Company Profiles (Introduction, Financial Analysis, Indication& Service Offerings, Key Developments, Strategies, and SWOT Analysis)
      • AstraZeneca plc (U.K.)
      • GlaxoSmithKline plc (U.K.)
      • Novartis AG (Switzerland)
      • Bristol Myers Squibb (U.S.)
      • Pfizer, Inc. (U.S.)
      • Sanofi S.A. (France)
      • Boehringer Ingelheim GmbH (Germany)
      • Johnson & Johnson Services, Inc. (U.S.)
      • Bayer AG (Germany)
      • Merck & Co., Inc. (U.S.)
      • Espero Pharmaceuticals, Inc. (U.S.)
  1. Research Methodology
  2. Key Assumptions and Acronyms

Report

Company Profile

  • Capsa Solutions LLC (U.S.)
  • Ergotron, Inc. (Melrose Industries plc) (UK)
  • Enovate Medical (U.S.)
  • Villard (France)
  • Parity Medical (UK)
  • InterMetro Industries Corp. (Emerson Electric) (U.S.)
  • Humanscale Healthcare (U.S.)
  • ITD GmBH (Germany)
  • Compucaddy (U.S.)
  • Advantech Co., Ltd. (China)
  • Bytech Healthcare Ltd. (U.K.)

Description

The global cardiovascular drugs market size valued $87.79 billion in 2020 and expected to reach $119.87 billion in 2027, at a CAGR of 4.8% during forecast period 2021-2027. Cardiovascular drugs are the medications used in the treatment of various cardiovascular diseases. Cardiovascular diseases (CVD) include coronary artery diseases (CAD), myocardial infarction, angina pectoris, hypertension, cardiomyopathy, congenital heart disease, cardiac arrhythmia, peripheral artery diseases, atherosclerosis, and venous thrombosis among others. Majority of the cardiovascular diseases are preventable with cardiovascular drugs, however, in frequent conditions death may occur due to cardiovascular diseases. Global Market has tremendous growth rate over the forecast years owing to increase in the prevalence of various cardiovascular diseases and rise in R&D activities for the innovation of newer drugs. According to World Health Organization 2015, approximately 17.7 Mn deaths occured due to cardiovascular diseases around the world. Moreover, government support to control the diseases, rise in funding from public and private sectors for the R&D activities, and patent expiration of blockbuster are bolster the cardiovascular drugs market. Furthermore, acquisitions and mergers, product approvals, and promising pipeline drugs might upsurge the revenue of cardiovascular drugs market. For instance, in November 2015, AstraZeneca acquired ZS Pharma to strengthen its cardiovascular drugs portfolio by developing novel treatment for hyperkalemia, typically associated with chronic heart failure (CHF). In addition, in June 2016, Espero Pharmaceuticals received FDA approval for Gonitro (Nitroglycerin) sublingual powder used for acute relief of an angina pectoris attack due to coronary artery disease.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX